Survival improvement in primary plasma cell leukemia: a retrospective analysis of novel agent-based regimens and stem cell transplantation
Despite novel agents, pPCL maintains poor prognosis, with treatment failure strongly associated with suboptimal first-line response. Therapeutic intensification through PIs/IMiDs with Ven (guided by t(11;14)) and ASCT consolidation may enhance depth of remission and survival outcomes.
Authors
- Jie He
- Y. C. Xu
- Hua Bai (ORCID: https://orcid.org/0000-0003-2221-7545)
- B Chen
- Lanxin Chen
- J. Liu
- Min Zhou
Institutions
- Nanjing Drum Tower Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-01-09
- DOI
- https://doi.org/10.3389/fonc.2025.1727117
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Nanjing Medical Science and Technique Development Foundation